Abstract

Making precision (personalized) medicine a routine clinical reality will require a comprehensive inventory of validated biomarkers and molecular diagnostic tests to stratify disease subtypes and improve accuracy in diagnosis and treatment selection. Realization of this promise has been hindered by the poor productivity of biomarker identification and validation. This situation reflects deficiencies that are pervasive across the entire spectrum of biomarker R&D, from discovery to clinical validation and in the failure of regulatory and reimbursement policies to accommodate new classes of biomarkers. The launch of the National Biomarker Development Alliance is the culmination of a 2-year review and consultation process involving diverse stakeholders to advance standards, best practices and guidelines to enhance biomarker discovery and validation by adoption of systems-based approaches and trans-sector collaboration between academia, clinical medicine and relevant private and public sector stakeholders.

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalExpert Review of Molecular Diagnostics
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Biomarkers
Research
Precision Medicine
Practice Guidelines
Private Sector
Molecular Pathology
Public Sector
Clinical Medicine
Routine Diagnostic Tests
Referral and Consultation
Equipment and Supplies
Therapeutics

Keywords

  • biomarkers
  • biospecimens
  • regulatory
  • reimbursement
  • standards
  • systems approaches
  • validation

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this

@article{3d156f5a8343403089bbba5b7d57e343,
title = "The national biomarker development alliance: Confronting the poor productivity of biomarker research and development",
abstract = "Making precision (personalized) medicine a routine clinical reality will require a comprehensive inventory of validated biomarkers and molecular diagnostic tests to stratify disease subtypes and improve accuracy in diagnosis and treatment selection. Realization of this promise has been hindered by the poor productivity of biomarker identification and validation. This situation reflects deficiencies that are pervasive across the entire spectrum of biomarker R&D, from discovery to clinical validation and in the failure of regulatory and reimbursement policies to accommodate new classes of biomarkers. The launch of the National Biomarker Development Alliance is the culmination of a 2-year review and consultation process involving diverse stakeholders to advance standards, best practices and guidelines to enhance biomarker discovery and validation by adoption of systems-based approaches and trans-sector collaboration between academia, clinical medicine and relevant private and public sector stakeholders.",
keywords = "biomarkers, biospecimens, regulatory, reimbursement, standards, systems approaches, validation",
author = "George Poste and Carolyn Compton and Anna Barker",
year = "2015",
month = "2",
day = "1",
doi = "10.1586/14737159.2015.974561",
language = "English (US)",
volume = "15",
pages = "211--218",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - The national biomarker development alliance

T2 - Confronting the poor productivity of biomarker research and development

AU - Poste, George

AU - Compton, Carolyn

AU - Barker, Anna

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Making precision (personalized) medicine a routine clinical reality will require a comprehensive inventory of validated biomarkers and molecular diagnostic tests to stratify disease subtypes and improve accuracy in diagnosis and treatment selection. Realization of this promise has been hindered by the poor productivity of biomarker identification and validation. This situation reflects deficiencies that are pervasive across the entire spectrum of biomarker R&D, from discovery to clinical validation and in the failure of regulatory and reimbursement policies to accommodate new classes of biomarkers. The launch of the National Biomarker Development Alliance is the culmination of a 2-year review and consultation process involving diverse stakeholders to advance standards, best practices and guidelines to enhance biomarker discovery and validation by adoption of systems-based approaches and trans-sector collaboration between academia, clinical medicine and relevant private and public sector stakeholders.

AB - Making precision (personalized) medicine a routine clinical reality will require a comprehensive inventory of validated biomarkers and molecular diagnostic tests to stratify disease subtypes and improve accuracy in diagnosis and treatment selection. Realization of this promise has been hindered by the poor productivity of biomarker identification and validation. This situation reflects deficiencies that are pervasive across the entire spectrum of biomarker R&D, from discovery to clinical validation and in the failure of regulatory and reimbursement policies to accommodate new classes of biomarkers. The launch of the National Biomarker Development Alliance is the culmination of a 2-year review and consultation process involving diverse stakeholders to advance standards, best practices and guidelines to enhance biomarker discovery and validation by adoption of systems-based approaches and trans-sector collaboration between academia, clinical medicine and relevant private and public sector stakeholders.

KW - biomarkers

KW - biospecimens

KW - regulatory

KW - reimbursement

KW - standards

KW - systems approaches

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=84921323111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921323111&partnerID=8YFLogxK

U2 - 10.1586/14737159.2015.974561

DO - 10.1586/14737159.2015.974561

M3 - Article

VL - 15

SP - 211

EP - 218

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7159

IS - 2

ER -